Regulatory Headwinds Threaten Hims & Hers’ Growth Trajectory

Investors in the telemedicine platform Hims & Hers are facing a complex investment landscape. While the company continues to demonstrate impressive operational growth, escalating regulatory challenges are creating significant uncertainty about its future prospects.

Strong Operational Performance Meets Regulatory Scrutiny

The company’s third-quarter 2025 results revealed substantial operational progress. Hims & Hers expanded its subscriber base by 21% to reach 2.47 million users, while average revenue per user climbed 19% to $80 monthly. Total revenue surged 49% to $599 million, demonstrating strong market demand for the company’s services.

However, this growth story faces potential disruption from regulatory pressures. In September 2025, the U.S. Food and Drug Administration issued warning letters to approximately 100 marketers, including Hims & Hers, concerning what the agency described as “false or misleading” marketing practices related to over-the-counter weight loss medications. This product category represents one of the platform’s most significant growth drivers, making the regulatory intervention particularly concerning.

Partnership Uncertainties and Financial Pressures

Compounding these regulatory challenges, discussions with pharmaceutical giant Novo Nordisk regarding a potential partnership for distributing Wegovy—the blockbuster weight management medication—have reportedly stalled. Although management characterizes these talks as “active discussions,” previous collaboration efforts with Novo Nordisk were terminated due to concerns about compounding practices.

The financial picture presents additional complexities. While adjusted EBITDA increased 53% to $78.4 million, indicating operational improvements, net profit declined sharply from $75.6 million to $15.8 million. This decrease was partially attributable to a $60.8 million tax benefit in the prior year period. The company’s margins remain under pressure during a phase requiring substantial investment in new therapeutic areas and international market expansion.

Should investors sell immediately? Or is it worth buying Hims & Hers?

Leadership Changes and Analyst Sentiment

Amid these challenges, Hims & Hers announced a significant leadership transition in early November. Chief Operating Officer Nader Kabbani transitioned from his operational role to an advisory position, with Mike Chi assuming expanded responsibilities. Such executive changes during a critical growth phase inevitably raise questions, despite management’s emphasis on continuity.

Market analysts remain divided in their assessments, with ratings spanning from “Strong Buy” to “Underperform.” Morgan Stanley maintains its neutral “Equal-Weight” rating with a $40 price target, reflecting the prevailing uncertainty. The company has narrowed its full-year revenue guidance to between $2.335 billion and $2.355 billion, suggesting more conservative expectations for the final quarter.

Financial Resources and Future Outlook

With $345.8 million in cash reserves, Hims & Hers maintains financial flexibility to navigate current challenges. However, the central question remains whether these resources will prove sufficient to simultaneously address regulatory hurdles, increasing competition, and margin pressures.

CEO Andrew Dudum’s ambitious target of $6.5 billion in revenue by 2030 appears increasingly dependent on securing strong partnerships within the lucrative weight management segment. The company’s ability to adapt its marketing practices while maintaining growth momentum will likely determine its success in overcoming the current regulatory obstacles and achieving its long-term objectives.